<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Lymphoma: Diagnosis and Treatment</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;700&family=Outfit:wght@700&display=swap" rel="stylesheet">
    <style>
        /* Custom Scrollbar for Webkit browsers */
        ::-webkit-scrollbar {
            width: 10px;
        }
        ::-webkit-scrollbar-track {
            background: #1f2937; /* Darker track */
            border-radius: 10px;
        }
        ::-webkit-scrollbar-thumb {
            background: #3b82f6; /* Tailwind's blue-500 */
            border-radius: 10px;
        }
        ::-webkit-scrollbar-thumb:hover {
            background: #2563eb; /* Tailwind's blue-600 */
        }

        .hero-background::before {
            content: '';
            position: absolute;
            top: 0;
            left: 0;
            right: 0;
            bottom: 0;
            background: linear-gradient(135deg, rgba(59, 130, 246, 0.1) 0%, rgba(139, 92, 246, 0.1) 50%, rgba(236, 72, 153, 0.1) 100%);
            filter: blur(120px);
            z-index: 0;
            opacity: 0.7;
        }

        .card-hover-effect {
            transition: transform 0.3s ease-in-out, box-shadow 0.3s ease-in-out, background-color 0.3s ease-in-out;
        }
        .card-hover-effect:hover {
            transform: translateY(-8px);
            box-shadow: 0 20px 40px rgba(0, 0, 0, 0.2), 0 10px 20px rgba(0, 0, 0, 0.1);
        }

        .gradient-text {
            background: linear-gradient(90deg, #3b82f6, #8b5cf6, #ec4899);
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
            color: transparent;
        }

        .section-divider {
            background: linear-gradient(to right, rgba(59, 130, 246, 0.5) 0%, rgba(139, 92, 246, 0.5) 50%, rgba(236, 72, 153, 0.5) 100%);
            height: 2px;
            width: 100%;
        }
    </style>
    <script>
        tailwind.config = {
            darkMode: 'class', // Enable dark mode class
            theme: {
                extend: {
                    colors: {
                        'primary-gradient-start': 'hsl(217, 77%, 60%)', // Tailwind's blue-500
                        'primary-gradient-end': 'hsl(260, 66%, 63%)',   // Tailwind's purple-500
                        'accent-gradient-end': 'hsl(330, 85%, 60%)',    // Tailwind's pink-500
                        'dark-bg': '#0f172a', // Tailwind's slate-900
                        'dark-card-bg': '#1e293b', // Tailwind's slate-800
                        'dark-text': '#e2e8f0', // Tailwind's slate-200
                        'dark-secondary-text': '#94a3b8', // Tailwind's slate-400
                    },
                    fontFamily: {
                        sans: ['Inter', 'sans-serif'], // Body font
                        display: ['Outfit', 'sans-serif'], // Heading font
                    },
                    keyframes: {
                        fadeInUp: {
                            '0%': { opacity: '0', transform: 'translateY(20px)' },
                            '100%': { opacity: '1', transform: 'translateY(0)' },
                        },
                        scaleUp: {
                            '0%': { transform: 'scale(0.95)', opacity: '0.9' },
                            '100%': { transform: 'scale(1)', opacity: '1' },
                        },
                        glow: {
                            '0%': { boxShadow: '0 0 10px rgba(59, 130, 246, 0.5)' },
                            '50%': { boxShadow: '0 0 20px rgba(139, 92, 246, 0.7)' },
                            '100%': { boxShadow: '0 0 10px rgba(236, 72, 153, 0.5)' },
                        }
                    },
                    animation: {
                        'fade-in-up': 'fadeInUp 0.8s ease-out forwards',
                        'scale-up': 'scaleUp 0.5s ease-out forwards',
                        'pulse-glow': 'glow 3s infinite',
                    }
                },
            },
        };
    </script>
</head>
<body class="font-sans antialiased bg-dark-bg text-dark-text p-6 md:p-12">

    <div class="relative min-h-screen w-full flex flex-col items-center justify-center overflow-hidden">
        <div class="hero-background absolute inset-0 -z-10"></div>

        <header class="relative z-10 w-full max-w-6xl mx-auto text-center mb-16 px-4">
            <h1 class="text-4xl md:text-6xl font-display font-bold mb-4 gradient-text animate-fade-in-up">
                Lymphoma: Diagnosis and Treatment
            </h1>
            <p class="text-lg md:text-xl text-dark-secondary-text animate-fade-in-up" style="animation-delay: 0.2s;">
                An In-depth Overview of Hematologic Malignancies
            </p>
        </header>

        <main class="relative z-10 w-full max-w-6xl mx-auto space-y-16">

            <!-- Section: Definition and Epidemiology -->
            <section id="definition-epidemiology" class="bg-dark-card-bg rounded-2xl p-8 md:p-12 shadow-xl card-hover-effect">
                <h2 class="font-display text-3xl md:text-4xl font-bold mb-6 text-primary-gradient-start">Definition and Epidemiology</h2>
                <p class="mb-6 text-dark-secondary-text">Lymphoma is a group of lymphoid neoplasms arising from the malignant transformation of lymphocytes (B-cells, T-cells, or NK-cells). It is broadly classified into two main types: Hodgkin Lymphoma (HL) and Non-Hodgkin Lymphoma (NHL).</p>
                <div class="grid grid-cols-1 md:grid-cols-2 gap-8">
                    <div>
                        <h3 class="text-xl font-bold mb-3 text-primary-gradient-start">Hodgkin Lymphoma (HL)</h3>
                        <ul class="list-disc list-inside space-y-2 text-dark-secondary-text pl-4">
                            <li>Characterized by Reed-Sternberg cells.</li>
                            <li>Accounts for ~10% of all lymphomas.</li>
                            <li>Incidence peaks in young adults (15-35) and adults over 55.</li>
                            <li>Overall incidence: ~2.5 per 100,000 person-years.</li>
                        </ul>
                    </div>
                    <div>
                        <h3 class="text-xl font-bold mb-3 text-accent-gradient-end">Non-Hodgkin Lymphoma (NHL)</h3>
                        <ul class="list-disc list-inside space-y-2 text-dark-secondary-text pl-4">
                            <li>More diverse group, ~90% of lymphomas.</li>
                            <li>Arises from B-cells (~85%), T-cells (~15%), or NK-cells.</li>
                            <li>Incidence increases with age (median diagnosis ~67 years).</li>
                            <li>Overall incidence: ~19.3 per 100,000 person-years.</li>
                            <li>Common subtypes: DLBCL (aggressive), FL (indolent).</li>
                        </ul>
                    </div>
                </div>
            </section>

            <!-- Section: Pathophysiology -->
            <section id="pathophysiology" class="bg-dark-card-bg rounded-2xl p-8 md:p-12 shadow-xl card-hover-effect">
                <h2 class="font-display text-3xl md:text-4xl font-bold mb-6 text-primary-gradient-start">Pathophysiology</h2>
                <p class="mb-6 text-dark-secondary-text">Lymphomas arise from acquired genetic mutations disrupting normal lymphocyte development, leading to uncontrolled growth. Triggers include viral infections (EBV, HTLV-1, HIV), immunodeficiency, autoimmune diseases, environmental exposures, and genetic predispositions.</p>
                <div class="grid grid-cols-1 lg:grid-cols-2 gap-8">
                    <div>
                        <h3 class="text-xl font-bold mb-3 text-primary-gradient-start">Hodgkin Lymphoma (HL)</h3>
                        <p class="text-dark-secondary-text mb-3">Malignant cells are a small fraction of the tumor mass; majority are reactive inflammatory cells. Genetic aberrations often involve NF-κB signaling activation.</p>
                    </div>
                    <div>
                        <h3 class="text-xl font-bold mb-3 text-accent-gradient-end">Non-Hodgkin Lymphoma (NHL)</h3>
                        <p class="text-dark-secondary-text mb-3">Diverse genetic alterations. DLBCL: chromosomal translocations (t(14;18), MYC, BCL6), epigenetic regulators mutations, NF-κB activation. FL: t(14;18) leading to BCL2 overexpression. MCL: t(11;14) causing cyclin D1 overexpression.</p>
                    </div>
                </div>
            </section>

            <!-- Section: Clinical Presentation -->
            <section id="clinical-presentation" class="bg-dark-card-bg rounded-2xl p-8 md:p-12 shadow-xl card-hover-effect">
                <h2 class="font-display text-3xl md:text-4xl font-bold mb-6 text-primary-gradient-start">Clinical Presentation</h2>
                <div class="grid grid-cols-1 md:grid-cols-2 gap-8">
                    <div>
                        <h3 class="text-xl font-bold mb-3 text-accent-gradient-end">Systemic "B" Symptoms</h3>
                        <p class="text-dark-secondary-text">Common in HL and aggressive NHL: unexplained fever (>38°C), drenching night sweats, and unexplained weight loss (>10% in 6 months).</p>
                    </div>
                    <div>
                        <h3 class="text-xl font-bold mb-3 text-accent-gradient-end">Lymphadenopathy</h3>
                        <p class="text-dark-secondary-text">Most common sign. HL: painless, firm, rubbery nodes (often cervical/mediastinal). NHL: any region, extranodal involvement more common.</p>
                    </div>
                </div>
                <div class="mt-8 grid grid-cols-1 md:grid-cols-2 gap-8">
                    <div>
                        <h3 class="text-xl font-bold mb-3 text-primary-gradient-start">Extranodal Disease</h3>
                        <p class="text-dark-secondary-text">More frequent in NHL, affecting GI tract, skin, bone marrow, CNS, spleen, liver.</p>
                    </div>
                    <div>
                        <h3 class="text-xl font-bold mb-3 text-primary-gradient-start">Specific Symptoms</h3>
                        <p class="text-dark-secondary-text">Pruritus and alcohol-induced pain (HL). Often asymptomatic (indolent FL). Rapid growth, B symptoms (aggressive DLBCL).</p>
                    </div>
                </div>
            </section>

            <!-- Section: Diagnostic Criteria -->
            <section id="diagnostic-criteria" class="bg-dark-card-bg rounded-2xl p-8 md:p-12 shadow-xl card-hover-effect">
                <h2 class="font-display text-3xl md:text-4xl font-bold mb-6 text-primary-gradient-start">Diagnostic Criteria</h2>
                <p class="mb-6 text-dark-secondary-text">Diagnosis relies on a multidisciplinary approach: clinical findings, histopathology, immunophenotyping, and molecular genetics.</p>
                <div class="grid grid-cols-1 md:grid-cols-2 lg:grid-cols-3 gap-6">
                    <div class="p-4 border-l-4 border-primary-gradient-start bg-dark-bg rounded-lg">
                        <h3 class="text-lg font-bold mb-2 text-white">1. Biopsy</h3>
                        <p class="text-dark-secondary-text text-sm">Excisional lymph node biopsy is gold standard.</p>
                    </div>
                    <div class="p-4 border-l-4 border-primary-gradient-start bg-dark-bg rounded-lg">
                        <h3 class="text-lg font-bold mb-2 text-white">2. Histopathology</h3>
                        <p class="text-dark-secondary-text text-sm">Expert review of morphology and architecture.</p>
                    </div>
                    <div class="p-4 border-l-4 border-primary-gradient-start bg-dark-bg rounded-lg">
                        <h3 class="text-lg font-bold mb-2 text-white">3. IHC & Flow Cytometry</h3>
                        <p class="text-dark-secondary-text text-sm">Immunophenotyping for lineage and specific markers.</p>
                    </div>
                    <div class="p-4 border-l-4 border-primary-gradient-start bg-dark-bg rounded-lg">
                        <h3 class="text-lg font-bold mb-2 text-white">4. Molecular/Cytogenetics</h3>
                        <p class="text-dark-secondary-text text-sm">Detect chromosomal translocations, mutations.</p>
                    </div>
                    <div class="p-4 border-l-4 border-primary-gradient-start bg-dark-bg rounded-lg">
                        <h3 class="text-lg font-bold mb-2 text-white">5. Staging Workup</h3>
                        <p class="text-dark-secondary-text text-sm">Physical exam, labs (LDH, CBC), PET-CT, CT scans.</p>
                    </div>
                    <div class="p-4 border-l-4 border-primary-gradient-start bg-dark-bg rounded-lg">
                        <h3 class="text-lg font-bold mb-2 text-white">6. Bone Marrow Biopsy</h3>
                        <p class="text-dark-secondary-text text-sm">Detects marrow involvement, esp. in NHL.</p>
                    </div>
                </div>
            </section>

            <!-- Section: Management -->
            <section id="management" class="bg-dark-card-bg rounded-2xl p-8 md:p-12 shadow-xl card-hover-effect">
                <h2 class="font-display text-3xl md:text-4xl font-bold mb-6 text-primary-gradient-start">Management Principles</h2>
                <p class="mb-6 text-dark-secondary-text">Treatment depends on subtype, stage, and prognostic factors. Key modalities include chemotherapy, immunotherapy, radiation therapy, and stem cell transplantation.</p>

                <div class="space-y-12">
                    <div>
                        <h3 class="text-2xl font-bold mb-4 text-accent-gradient-end">Hodgkin Lymphoma (HL)</h3>
                        <div class="grid grid-cols-1 lg:grid-cols-2 gap-8">
                            <div>
                                <h4 class="text-lg font-semibold mb-3 text-dark-text">First-line Treatment</h4>
                                <ul class="list-disc list-inside space-y-2 text-dark-secondary-text pl-4">
                                    <li><strong>Early Stage:</strong> ABVD (2-4 cycles) + ISRT.</li>
                                    <li><strong>Advanced Stage:</strong> ABVD (6-8 cycles) or Brentuximab Vedotin + AVD (preferred). Escalated BEACOPP for high-risk.</li>
                                </ul>
                            </div>
                            <div>
                                <h4 class="text-lg font-semibold mb-3 text-dark-text">Relapsed/Refractory</h4>
                                <ul class="list-disc list-inside space-y-2 text-dark-secondary-text pl-4">
                                    <li>High-dose chemo + ASCT.</li>
                                    <li>Brentuximab Vedotin.</li>
                                    <li>PD-1 inhibitors (Nivolumab, Pembrolizumab).</li>
                                </ul>
                            </div>
                        </div>
                    </div>

                    <div>
                        <h3 class="text-2xl font-bold mb-4 text-primary-gradient-start">Non-Hodgkin Lymphoma (NHL)</h3>
                        <div class="grid grid-cols-1 md:grid-cols-2 gap-8">
                            <div>
                                <h4 class="text-lg font-semibold mb-3 text-dark-text">Diffuse Large B-cell Lymphoma (DLBCL)</h4>
                                <ul class="list-disc list-inside space-y-2 text-dark-secondary-text pl-4">
                                    <li><strong>First-line:</strong> R-CHOP (6 cycles). Polatuzumab Vedotin + R-CHP is preferred for intermediate/high-risk.</li>
                                    <li><strong>Relapsed/Refractory:</strong> ASCT, CAR T-cell therapy, Tafasitamab + lenalidomide, Loncastuximab tesirine.</li>
                                </ul>
                            </div>
                            <div>
                                <h4 class="text-lg font-semibold mb-3 text-dark-text">Follicular Lymphoma (FL)</h4>
                                <ul class="list-disc list-inside space-y-2 text-dark-secondary-text pl-4">
                                    <li><strong>First-line:</strong> R-Bendamustine (BR) or R-CHOP. Watch and Wait for asymptomatic low burden.</li>
                                    <li><strong>Relapsed/Refractory:</strong> BR, R², PI3K inhibitors, CAR T-cell therapy.</li>
                                </ul>
                            </div>
                        </div>
                        <div class="mt-8">
                            <h4 class="text-lg font-semibold mb-3 text-dark-text">Mantle Cell Lymphoma (MCL)</h4>
                            <ul class="list-disc list-inside space-y-2 text-dark-secondary-text pl-4">
                                <li><strong>First-line:</strong> Intensive chemo + ASCT (young/fit), R-Bendamustine (older/less fit).</li>
                                <li><strong>Relapsed/Refractory:</strong> BTK inhibitors (Ibrutinib, Acalabrutinib, Zanubrutinib), CAR T-cell therapy.</li>
                            </ul>
                        </div>
                    </div>
                </div>
            </section>

            <!-- Section: Special Populations & Updates -->
            <section id="updates" class="bg-dark-card-bg rounded-2xl p-8 md:p-12 shadow-xl card-hover-effect">
                <h2 class="font-display text-3xl md:text-4xl font-bold mb-6 text-primary-gradient-start">Special Populations & Landmark Updates</h2>
                <div class="grid grid-cols-1 md:grid-cols-2 gap-8">
                    <div>
                        <h3 class="text-xl font-bold mb-3 text-accent-gradient-end">Special Populations</h3>
                        <p class="text-dark-secondary-text mb-3">Management tailored for pregnant patients, elderly, HIV-associated lymphoma, and Primary CNS Lymphoma (high-dose methotrexate-based regimens).</p>
                    </div>
                    <div>
                        <h3 class="text-xl font-bold mb-3 text-accent-gradient-end">Recent Updates & Trials</h3>
                        <p class="text-dark-secondary-text mb-3">
                            <strong>HL:</strong> ECHELON-1 (BV+AVD preferred).
                            <strong>DLBCL:</strong> POLARIX (Polatu+R-CHP preferred). CAR T-cell therapy superior to salvage chemo for relapsed/refractory.
                            <strong>FL:</strong> Watch and Wait valid. Obinutuzumab-based therapy showed PFS benefit.
                            <strong>MCL:</strong> BTK inhibitors revolutionized relapsed/refractory treatment.
                        </p>
                    </div>
                </div>
            </section>

            <!-- Section: References -->
            <section id="references" class="bg-dark-card-bg rounded-2xl p-8 md:p-12 shadow-xl card-hover-effect">
                <h2 class="font-display text-3xl md:text-4xl font-bold mb-6 text-primary-gradient-start">References</h2>
                <div class="grid grid-cols-1 md:grid-cols-2 gap-6">
                    <ul class="list-disc list-inside space-y-3 text-dark-secondary-text">
                        <li>Armitage, J. O. (2010). The lymphomas. *Blood*.</li>
                        <li>Ansell, S. M. (2017). Hodgkin Lymphoma: 2017 Update. *Am J Hematol*.</li>
                        <li>SEER Program. National Cancer Institute. *Cancer Stat Facts: Lymphoma*.</li>
                        <li>Jaffe, E. S., et al. (2017). WHO Classification of Lymphoid Neoplasms: 2016 revision. *Blood*.</li>
                        <li>IARC. (2019). *World Cancer Report*.</li>
                        <li>Morton, L. M., et al. (2008). Etiologic heterogeneity of non-Hodgkin lymphoma subtypes. *Seminars in Cancer Biology*.</li>
                        <li>Küppers, R. (2009). The biology of Hodgkin lymphoma. *Nature Reviews Cancer*.</li>
                        <li>Swerdlow, S. H., et al. (2016). The 2016 revision of the World Health Organization classification. *Blood*.</li>
                        <li>Cheson, B. D., & Fisher, R. I. (2020). Follicular Lymphoma. *J Clin Oncol*.</li>
                        <li>Wang, M. L., & Hagemeister, F. (2013). Mantle cell lymphoma. *J Hematol Oncol*.</li>
                    </ul>
                    <ul class="list-disc list-inside space-y-3 text-dark-secondary-text">
                        <li>NCCN. (2025). *NCCN Guidelines®*.</li>
                        <li>Cheson, B. D., & O'Sullivan, J. M. (2014). PET in lymphoma. *J Clin Oncol*.</li>
                        <li>Connors, J. M., et al. (2018). Brentuximab Vedotin with Chemotherapy for Stage III/IV Hodgkin's Lymphoma. *N Engl J Med*.</li>
                        <li>Younes, A., et al. (2012). Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. *J Clin Oncol*.</li>
                        <li>Armand, P., et al. (2018). Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma. *J Clin Oncol*.</li>
                        <li>Coiffier, B., et al. (2002). CHOP plus rituximab vs CHOP alone in elderly patients with diffuse large-B-cell lymphoma. *N Engl J Med*.</li>
                        <li>Wilson, W. H., et al. (2017). Chemoimmunotherapy With Dose-Adjusted EPOCH-R in Diffuse Large B-Cell Lymphoma. *N Engl J Med*.</li>
                        <li>Tilly, H., et al. (2022). Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. *N Engl J Med*.</li>
                        <li>Neelapu, S. S., et al. (2017). Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. *N Engl J Med*.</li>
                        <li>Schuster, S. J., et al. (2019). Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. *N Engl J Med*.</li>
                    </ul>
                </div>
            </section>

        </main>
    </div>

    <script>
        // Optional: Add subtle animations on scroll or for interactive elements
        document.addEventListener('DOMContentLoaded', () => {
            const observer = new IntersectionObserver((entries) => {
                entries.forEach(entry => {
                    if (entry.isIntersecting) {
                        entry.target.classList.add('animate-scale-up');
                        observer.unobserve(entry.target);
                    }
                });
            }, { threshold: 0.1 }); // Trigger when 10% of the element is visible

            document.querySelectorAll('.card-hover-effect').forEach(card => {
                observer.observe(card);
            });

            // Ensure all fade-in-up elements are visible on load
            document.querySelectorAll('.animate-fade-in-up').forEach((el, index) => {
                el.style.animationDelay = `${index * 0.1}s`;
                el.classList.add('animate-fade-in-up');
            });
        });
    </script>
</body>
</html>
